ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

KRRO Korro Bio Inc

45.83
-0.80 (-1.72%)
Last Updated: 17:22:43
Delayed by 15 minutes
Share Name Share Symbol Market Type
Korro Bio Inc NASDAQ:KRRO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.80 -1.72% 45.83 45.49 46.10 48.1899 45.6315 45.75 51,306 17:22:43

Korro to Participate in Upcoming Investor Conferences

10/09/2024 1:00pm

GlobeNewswire Inc.


Korro Bio (NASDAQ:KRRO)
Historical Stock Chart


From Aug 2024 to Nov 2024

Click Here for more Korro Bio Charts.

Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor conferences:

2024 Cantor Global Healthcare ConferenceTodd Chappell, Chief Operating Officer, will participate in a fireside chat on Tuesday, September 17, 2024, at 10:55 a.m. ET. Vineet Agarwal, Chief Financial Officer, will also participate in 1x1 investor meetings at the conference.

Chardan’s 8th Annual Genetic Medicines ConferenceRam Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Monday, September 30, 2024, at 2:30 p.m. ET. Mr. Agarwal will also be participating at the conference.

The live webcasts of the Cantor and Chardan fireside chats can be accessed on the “Events & Presentations” page in the Investor section of Korro’s website at www.korrobio.com. Following the presentations, a replay of the event will be available for 30 days.

About Korro Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to affect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.

Korro Contact Information

InvestorsIR@korrobio.com 

MediaGlenn Silver FINN Partners Glenn.silver@finnpartners.com 

1 Year Korro Bio Chart

1 Year Korro Bio Chart

1 Month Korro Bio Chart

1 Month Korro Bio Chart